Immunic, INC 8-K filings

Immunic, Inc. CEO Daniel Vitt will temporarily relocate to the United States, leading to a new employment agreement and a pause in his service on the management board of Immunic AG.

Immunic, Inc. reported positive interim analysis results for its Phase 3 ENSURE program in relapsing multiple sclerosis and announced its third quarter 2024 financial results.

Immunic's Phase 3 ENSURE program for relapsing multiple sclerosis treatment, using vidofludimus calcium, has successfully passed its interim futility analysis, allowing the trial to continue as planned.

Immunic, Inc. held a research and development day highlighting their work on vidofludimus calcium (IMU-838) for treating multiple sclerosis.

Immunic, Inc. has extended the employment term of its Executive Chairman, Dr. Duane Nash, to December 31, 2025, and increased his monthly base salary.

Immunic, Inc. reported its second quarter 2024 financial results, provided a corporate update, and announced key leadership appointments.

Immunic, Inc. has appointed Simona Skerjanec, a seasoned pharmaceutical executive with extensive experience in neurology and commercialization, to its board of directors, effective July 22, 2024.

Immunic, Inc. has appointed Jason Tardio as Chief Operating Officer and President and promoted Werner Gladdines to Chief Development Officer to strengthen its leadership team as it prepares for potential commercialization of its lead drug candidate.

Immunic, Inc. held its annual meeting of stockholders on June 11, 2024, where key proposals were voted on and approved.

Immunic, Inc. announced its first quarter 2024 financial results, highlighted by a substantial private placement and progress in its clinical programs for multiple sclerosis and celiac disease.

Immunic Inc. has increased its authorized common stock shares from 130 million to 500 million and approved amendments to its employee stock purchase and equity incentive plans.

Immunic, Inc. reported its year-end 2023 financial results, highlighted by a significant $240 million private placement and progress in its clinical programs for multiple sclerosis and celiac disease.